Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review

Clinical Reviews in Allergy and Immunology

Volumn 52, Issue 2, 2017, Pages 194-201

  Slobodin, Gleb ^a,b   Rimar, Doron ^a,b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Regulatory T cells; Skin resident regulatory T cells; Systemic sclerosis

Indexed keywords

ILOPROST;

APOPTOSIS; AUTOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; EFFECTOR CELL; HUMAN; IMMUNE SYSTEM; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC SCLEROSIS; TH17 CELL; TH2 CELL; IMMUNOLOGY;

HUMANS; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES, REGULATORY;

EID: 84975155671     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-016-8563-6     Document Type: Review

References (72)

1. Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24(2):165–170
2. Elhai M, Avouac J, Walker UA et al (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75(1):163–169
3. Denton CP (2015) Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol 33(4 Suppl 92):S3–S7
4. Krieg T, Takehara K (2009) Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii14–iii18
5. Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815
6. Desbois AC, Cacoub P (2016) Systemic sclerosis: an update in 2016. Autoimmun Rev 15:417–426
7. Meier FM, Frommer KW, Dinser R et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360
8. Coghlan JG, Denton CP, Grunig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340–1349
9. Amaral TN, Peres FA, Lapa AT et al (2013) Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 43:335–347
10. Maurer B, Distler A, Suliman YA et al (2014) Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 73:1880–1887
11. Kawaguchi Y, Suzuki K, Hara M et al (1994) Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 53(8):506–510
12. Lee R, Reese C, Perry B et al (2015) Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1. Fibrogenesis Tissue Repair 8:11. doi:10.1186/s13069-015-0028-7
13. Van Bon L, Affandi AJ, Broen J et al (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 370:433–443
14. Pisitkun P, Deane JA, Difilippantonio MJ et al (2006) Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312(5780):1669–1672
15. Eloranta ML, Franck-Larsson K, Lövgren T et al (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 69(7):1396–1402
16. Dimitroulas T, Daoussis D, Garyfallos A, Sfikakis PP, Kitas GD (2015) Molecular and cellular pathways as treatment targets for biologic therpaies in systemic sclerosis. Curr Med Chem 22(16):1943–1955
17. Gottenberg JE, Chiocchia G (2007) Dendritic cells and interferon-mediated autoimmunity. Biochimie 89(6-7):856–871
18. Huang XL, Wang YJ, Yan JW et al (2015) Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis. Inflamm Res 64(3-4):151–159
19. Liu M, Yang J, Xing X et al (2014) Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res Ther 16(6):4223
20. Stummvoll GH, Aringer M, Smolen JS et al (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39(12):1341–1350
21. Nie J, Li YY, Zheng SG et al (2015) FOXP3(+) Treg Cells and Gender Bias in Autoimmune Diseases. Front Immunol 6:493. doi:10.3389/fimmu.2015.00493
22. Liston A, Gray DH (2014) Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 14(3):154–165
23. Chizzolini C, Boin F (2015) The role of the acquired immune response in systemic sclerosis. Semin Immunopathol 37(5):519–528
24. Ohkura N, Hamaguchi M, Morikawa H et al (2012) T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37(5):785–799
25. Amado IF, Berges J, Luther RJ et al (2013) IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med 210(12):2707–2720
26. Miyara M, Yoshioka Y, Kitoh A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6):899–911
27. Pesenacker AM, Broady R, Levings MK (2014) Control of tissue-localized immune responses by human regulatory T cells. Eur J Immunol 45(2):333–343
28. Sanchez Rodriguez R, Pauli ML, Neuhaus IM et al (2014) Memory regulatory T cells reside in human skin. J Clin Invest 124(3):1027–1036
29. Nomura T, Kabashima K, Miyachi Y (2014) The panoply of αβT cells in the skin. J Dermatol Sci 76(1):3–9
30. Seneschal J, Clark RA, Gehad A et al (2012) Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 36(5):873–884
31. Dudda JC, Perdue N, Bachtanian E et al (2008) Foxp3+ regulatory T cells maintain immune homeostasis in the skin. J Exp Med 205(7):1559–1565
32. Stary G, Klein I, Bauer W et al (2011) Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells. J Immunol 186(1):103–112
33. Chu CC, Ali N, Karagiannis P et al (2012) Resident CD141 (BDCA3) + dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 209(5):935–945
34. Tomura M, Honda T, Tanizaki H et al (2010) Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 120(3):883–893
35. Sawant DV, Vignali DA (2014) Once a Treg, always a Treg? Immunol Rev 259(1):173–191
36. Pesenacker AM, Bending D, Ursu S et al (2013) CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood 121(14):2647–2658
37. Duhen T, Duhen R, Lanzavecchia A et al (2012) Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119(19):4430–4440
38. McClymont SA, Putnam AL, Lee MR et al (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186(7):3918–3926
39. Radstake TR, van Bon L, Broen J et al (2009) Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 4(6):e5981
40. Simonetta F, Chiali A, Cordier C et al (2010) Increased CD127 expression on activated FOXP3 + CD4+ regulatory T cells. Eur J Immunol 40(9):2528–2538
41. Giovannetti A, Rosato E, Renzi C et al (2010) Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 137(1):122–133
42. Slobodin G, Ahmad MS, Rosner I et al (2010) Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 261(2):77–80
43. Liu X, Gao N, Li M et al (2013) Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One 8(6):e64531
44. + regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin Med J (Engl) 127(20):3557–3561
45. Rodríguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J et al (2012) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 32(9):2653–2660
46. Klein S, Kretz CC, Krammer PH et al (2010) CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol 130(2):492–499
47. Klein S, Kretz CC, Ruland V et al (2011) Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 70(8):1475–1481
48. Banica L, Besliu A, Pistol G et al (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42(1):41–49
49. Antiga E, Quaglino P, Bellandi S et al (2010) Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 162(5):1056–1063
50. Papp G, Horvath IF, Barath S et al (2011) Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 40(3):205–210
51. Fenoglio D, Battaglia F, Parodi A et al (2011) Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 139(3):249–257
52. Cordiali-Fei P, Mussi A, D’Agosto G et al (2013) Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol 2013:390563
53. Reiff A, Weinberg KI, Triche T et al (2013) T lymphocyte abnormalities in juvenile systemic sclerosis patients. Clin Immunol 149(1):146–155
54. Mathian A, Parizot C, Dorgham K et al (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71(7):1227–1234
55. + regulatory T cells in systemic sclerosis. Mod Rheumatol 25(1):90–95
56. Michels-van Amelsfort JM, Walter GJ, Taams LS (2011) CD4 + CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases. Expert Rev Clin Immunol 7(4):499–514
57. Antiga E, Fabbri P, Caproni M (2010) Immunosuppressive therapy may affect the number of circulating regulatory cells in systemic sclerosis: pay attention to the patient selection criteria. Cell Immunol 264(2):186
58. D’Amelio P, Cristofaro MA, D’Amico L et al (2010) Iloprost modulates the immune response in systemic sclerosis. BMC Immunol 11:62
59. Papp G, Horvath IF, Barath S et al (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142(2):150–159
60. Papp G, Barath S, Szegedi A et al (2012) The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol 31(9):1293–1299
61. Tsukamoto H, Nagafuji K, Horiuchi T et al (2011) Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells. Rheumatology (Oxford) 50(5):944–952
62. Baraut J, Grigore EI, Jean-Louis F et al (2014) Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant 49(3):349–354
63. Szodoray P, Varoczy L, Papp G et al (2012) Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol 41(2):110–115
64. Delemarre EM, van den Broek T, Mijnheer G et al (2016) Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood 127(1):91–101
65. Broen JC, Wolvers-Tettero IL, Geurts-van Bon L et al (2010) Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Ann Rheum Dis 69(12):2213–2216
66. Wang YY, Wang Q, Sun XH et al (2014) DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol 171(1):39–47
67. Giovannetti A, Maselli A, Colasanti T et al (2013) Autoantibodies to estrogen receptor α in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PLoS One 8(9):e74332
68. Rimar D, Nov Y, Rosner I et al (2015) Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int 35(10):1625–1630
69. Khoury SJ (2011) Th17 and Treg balance in systemic sclerosis. Clin Immunol 139(3):231–232
70. Liu M, Wu W, Sun X, et al. (2016) New insights into CD4(+) T cell abnormalities in systemic sclerosis. Cytokine Growth Factor Rev 28:31–36
71. Yang X, Yang J, Xing X et al (2014) Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 16(1):R4
72. MacDonald KG, Dawson NA, Huang Q et al (2015) Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol 135(4):946, e9